Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University/OHSU, Portland, OR, USA.
Izon Science Ltd, Cambridge, MA, USA.
Nanomedicine. 2019 Jun;18:146-156. doi: 10.1016/j.nano.2019.02.019. Epub 2019 Mar 13.
Successful liposomal formulations in the clinic are severely limited due to poor translational capability of the traditional bench techniques to clinical production settings. The gold standard for liposome bench manufacturing is a multi-step and parameter dependent extrusion method. Moreover, these parameters need re-optimization for clinical production. The microfluidics technique utilizes vigorous mixing of fluids at a nanoliter scale to produce liposomes in batches from milliliters to a couple liters. The fine control of process parameters results in improved reproducibility between batches. It is inherently scalable; however, the characteristics of liposomes produced by microfluidics both in vitro and in vivo have never been compared to those produced using extrusion. In this manuscript, we describe the comparison between the traditional extrusion method to microfluidics, the new paradigm in liposome production and scale-up.
由于传统的实验室技术向临床生产环境的转化能力较差,临床上成功的脂质体制剂受到严重限制。脂质体实验室生产的金标准是多步且依赖参数的挤出方法。此外,这些参数需要重新优化以用于临床生产。微流控技术利用在纳升级别对流体进行剧烈混合,从毫升到几升批量生产脂质体。精细控制工艺参数可提高批次间的重现性。它具有固有扩展性;然而,微流控技术在体外和体内生产的脂质体的特性从未与挤出方法生产的脂质体进行过比较。在本文中,我们描述了传统挤出方法与微流控技术之间的比较,这是脂质体制备和放大的新模式。